Potential for radiation therapy technology innovations to permit dose escalation for non-small-cell lung cancer

Clinical Lung Cancer

Volumn 7, Issue 2, 2005, Pages 107-113

  Mañon, Rafael R ^a   Jaradat, Hazim ^b   Patel, Rakesh ^b   Zhang, Tiezhi ^b   Fenwick, John ^b   Tomé, Wolfgang ^b   Fowler, Jack ^b   Paliwal, Bhudatt ^b   Soisson, Emilie ^c   Yuan, Zhilong ^d   Mehta, Minesh ^b  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Dose volume histogram; Maximum inspiration breath hold technique; Pneumonitis

Indexed keywords

ARTICLE; BREATH HOLDING; BREATHING; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; EXHALATION; HISTOGRAM; HUMAN; INHALATION; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; LUNG VOLUME; MEASUREMENT; MOTION; PNEUMONIA; RADIATION DOSE; SIMULATION; TREATMENT PLANNING; TUMOR;

EID: 32044459945     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2005.n.025     Document Type: Article

References (32)

1. Perez CA, Stanley K, Grundy G, et al. Longterm observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 1987; 59:1874-1881.
2. Cox JD, Azarnia N, Byhardt RW, et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncal 1990; 8:1543-1555.
3. Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997; 350:161-165.
4. Martel MK, Ten Haken RK, Hazuka MB, et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 1999; 24:31-37.
5. Manon R, Mehta M. Strategies for enhanced radiation delivery in patients with lung cancer. Exp Opin Drug Del 2005; 2:103-113.
6. Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001; 19:127-136.
7. Hanley J, Debois MM, Mah D, et al. Deep inspiration breath-hold technique for lung tumors: the potential value of target immobilization and reduced lung density in dose escalation. Int J Radiat Oncol Biol Phys 1999; 45:603-611.
8. Rosenzweig KE, Hanley J, Mah D, et al. The deep inspiration breath-hold technique in the treatment of inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2000; 48:81-87.
9. Scrimger RA, Tome WA, Olivera GH, et al. Reduction in radiation dose to lung and other normal tissues using helical tomotherapy to treat lung cancer, in comparison to conventional field arrangements. Am J Clin Oncol 2003; 26:70-78.
10. Zhang T, Keller H, O'Brien MJ, et al. Application of the spirometer in respiratory gated radiotherapy. Med Phys 2003; 30:3165-3171.
11. Giraud P, Antoine M, Larrouy A, et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 2000; 48:1015-1024.
12. Seppenwoolde Y, Shirato H, Kitamura K, et al. Precise and real-time measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy. Int J Radiat Oncol Biol Phys 2002; 53:822-834.
13. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999; 45:323-329.
14. Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 1998; 42:1-9.
15. Tome WA, Fowler JF. On cold spots in tumor subvolumes. Med Phys 2002; 29:1590-1598.
16. Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys 1997; 24:103-110.
17. Mehta M, Scrimger R, Mackie R, et al. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001; 49:23-33.
18. Stevens CW, Munden RF, Forster KM, et al. Respiratory-driven lung tumor motion is independent of tumor size, tumor location, and pulmonary function. Int J Radiat Oncol Biol Phys 2001; 51:62-68.
19. Wong JW, Sharpe MB, Jaffray DA, et al. The use of active breathing control (ABC) to reduce margin for breathing motion. Int J Radiat Oncol Biol Phys 1999; 44:911-919.
20. Keall PJ, Kini VR, Vedam SS, et al. Motion adaptive x-ray therapy: a feasibility study. Phys Med Biol 2001; 46:1-10.
21. Jiang S NT, Chen GT. Gated motion adaptive therapy: a new modality for treating mobile tumors. Int J Radiat Oncol Biol Phys 2002; 54(suppl):S195.
22. Tada T, Minakuchi K, Fujioka T, et al. Lung cancer: intermittent irradiation synchronized with respiratory motion - results of a pilot study. Radiology 1998; 207:779-783.
23. Zhang T, Keller H, Jeraj R, et al. Breathing synchronized delivery-a new technique for radiation treatment of targets with respiratory motion. Int J Radiat Oncol Biol Phys 2003; 57(suppl):S185.
24. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003; 124:1946-1955.
25. Timmerman RD, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2003; 57(suppl):S480.
26. Gomi K, Oguchi M. Clinical experience of stereotactic radiation therapy for stage IA non-small cell lung cancer. Presented at: Sixth International Stereotactic Radiosurgery Society Congress; June 22-26, 2003; Kyoto, Japan. Abstract OSS X-1.
27. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 94-10. Proc Am Soc Clin Oncol 2003; 22:621 (Abstract #2499).
28. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88:1210-1215.
29. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83:417-423.
30. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:2692-2699.
31. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87:198-205.
32. Fowler JF, Chappell R. Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys 2000; 46:516-517.